Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study
- 1 June 2007
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 109 (11) , 4693-4697
Abstract
It has been suggested that plasma-derived factor VIII products induce fewer inhibitors than recombinant factor VIII products. We investigated the relationship of factor VIII product type and switching between factor VIII products with the risk to develop inhibitors. This multicenter retrospective cohort study included 316 patients with severe hemophilia A born between 1990 and 2000. The outcome was clinically relevant inhibitor development, defined as the occurrence of at least 2 positive inhibitor titers with decreased recovery. The risk of inhibitor development was not clearly lower in plasma-derived compared with recombinant factor VIII products (relative risk [RR], 0.8; 95% confidence interval [CI], 0.5-1.3). Among high-titer inhibitors, the possible reduction in risk was even less pronounced (RR, 0.9; CI, 0.5-1.5). Plasma-derived products with considerable quantities of von Willebrand factor (VWF) carried the same risk for inhibitor development as recombinant factor VIII products (RR, 1.0; CI, 0.6-1.6). Switching between factor VIII products did not increase the risk for inhibitors (RR, 1.1; CI, 0.6-1.8). In conclusion, our findings support neither the notion that plasma-derived factor VIII products with considerable concentrations of VWF confer a lower risk to develop inhibitory antibodies than recombinant factor VIII products, nor that switching between factor VIII product brands increases inhibitor risks in previously untreated patients with severe hemophilia A.Keywords
This publication has 39 references indexed in Scilit:
- The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an updateHaemophilia, 2005
- Prophylactic treatment effects on inhibitor risk: experience in one centreHaemophilia, 2005
- Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigationJournal of Thrombosis and Haemostasis, 2004
- The Molecular Basis of Hemophilia A: Genotype-Phenotype Relationships and Inhibitor DevelopmentSeminars in Thrombosis and Hemostasis, 2003
- Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIIIHaemophilia, 2001
- Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparationsHaemophilia, 1996
- Recombinate: viral safety and final product manufacturing testing and specificationsAnnals of Hematology, 1994
- Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type IIIAnnals of Hematology, 1992
- Relation of pooled logistic regression to time dependent cox regression analysis: The framingham heart studyStatistics in Medicine, 1990
- Genetic predisposition to develop factor VIII antibody in classic hemophiliaClinical Immunology and Immunopathology, 1977